

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

**INSIDE INFORMATION
COMPLETION OF
THE PUBLIC ISSUANCE OF
THE THIRD TRANCHE OF 2026 CORPORATE BONDS
IN THE PRC**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of China Resources Pharmaceutical Group Limited (the “**Company**”) dated 27 March 2026 and 28 April 2026 (the “**Announcements**”) in relation to, among others, the first tranche and second tranche of 2026 Corporate Bonds in the PRC. Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless stated otherwise herein.

The Board is pleased to announce that China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司) (“**CR Pharmaceutical Commercial**”), a non-wholly-owned subsidiary of the Company, has completed public issuance of the third tranche of the 2026 Corporate Bonds in the PRC. The third tranche of the 2026 Corporate Bonds has been issued in a principal amount of RMB2 billion, with a term of three years and a coupon rate of 1.59% per annum.

The net proceeds raised from the issuance of the third tranche of the 2026 Corporate Bonds will be used for production expenditures, including replenishment of working capital, repayment of interest-bearing debts, project investments, and other purposes in compliance with applicable laws and regulations.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 26 June 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive director of the Company; Mr. Cheng Jie and Mr. Liu Changan as executive directors of the Company; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive directors of the Company and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive directors of the Company.